ZVRA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.40%

Insider Buying (Last 12 Months): $140,340.00

Insider Selling (Last 12 Months): $0.00

Zevra Therapeutics Insider Trading History Chart

Zevra Therapeutics Share Price & Price History

^$7.83

▲ +0.3 (3.98%)

As of 09/18/2024 01:00 AM ET

Days: 30 | 90 | 365

Kamala Harris and The Woke Progressive Nightmare

From Paradigm Press | Ad

New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.

Click here now to see Jim’s shocking predictions for November.

Zevra Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2024	R. Laduane Clifton	CFO	Buy	2,000	$6.77	$13,540.00	18,469
7/16/2024	Thomas Anderson	Director	Buy	10,000	$6.81	$68,100.00	20,000
7/12/2024	John B Bode	Director	Buy	10,000	$5.87	$58,700.00	30,000
9/6/2023	R. Laduane Clifton	CFO	Buy	1,000	$4.96	$4,960.00	15,309
9/5/2023	John B Bode	Director	Buy	10,000	$5.13	$51,300.00	20,000
9/5/2023	Joshua Schafer	EVP	Buy	500	$5.13	$2,565.00	3,500
6/23/2023	Corey Michael Watton	Director	Buy	275	$5.95	$1,636.25	1,000
6/9/2023	Corey Michael Watton	Director	Buy	325	$5.52	$1,794.00	725
5/30/2023	Corey Michael Watton	Director	Buy	400	$5.11	$2,044.00	400
5/19/2023	Joshua Schafer	EVP	Buy	1,000	$5.42	$5,420.00	3,000
5/18/2023	John B Bode	Director	Buy	10,000	$5.04	$50,400.00	10,000
5/18/2023	R. Laduane Clifton	CFO	Buy	2,740	$4.95	$13,563.00	13,742
3/17/2023	Tamara A Seymour	Director	Buy	519	$4.82	$2,501.58	719
3/14/2023	Joshua Schafer	EVP	Buy	2,000	$4.61	$9,220.00	2,000
3/10/2023	R. Laduane Clifton	CFO	Buy	1,725	$4.15	$7,158.75	11,002
3/10/2023	Timothy J Sangiovanni	SVP	Buy	1,200	$4.14	$4,968.00	4,449
3/9/2023	Matthew R Plooster	Director	Buy	11,000	$4.20	$46,200.00	18,500
3/9/2023	Richard W Pascoe	CEO	Buy	10,000	$4.20	$42,000.00	29,973

Kamala Harris and The Woke Progressive Nightmare

From Paradigm Press | Ad

New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.

Click here now to see Jim’s shocking predictions for November.

SEC Filings (Institutional Ownership Changes) for Zevra Therapeutics (NASDAQ:ZVRA)

35.03% of Zevra Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Zevra Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/5/2024	Sanctuary Advisors LLC	104,924	$0.47M	0.0%	N/A	0.199%
8/20/2024	Nantahala Capital Management LLC	2,419,435	$11.86M	0.7%	-1.4%	5.781%
8/15/2024	The Manufacturers Life Insurance Company	18,573	$91K	0.0%	+15.2%	0.044%
8/9/2024	Renaissance Technologies LLC	112,800	$0.55M	0.0%	-27.4%	0.270%
8/9/2024	Retirement Planning Co of New England Inc.	458,300	$2.25M	1.2%	+6.5%	1.095%
8/9/2024	Mystic Asset Management Inc.	297,947	$1.46M	0.6%	+11.9%	0.712%
8/1/2024	Rhumbline Advisers	56,874	$0.28M	0.0%	+17.9%	0.136%
7/26/2024	Bank of New York Mellon Corp	220,499	$1.08M	0.0%	+10.7%	0.527%
5/16/2024	Jacobs Levy Equity Management Inc.	34,707	$0.20M	0.0%	+102.4%	0.083%
5/15/2024	Price T Rowe Associates Inc. MD	11,011	$64K	0.0%	N/A	0.026%
5/10/2024	Vanguard Group Inc.	1,704,006	$9.88M	0.0%	+3.6%	3.924%
5/7/2024	Retirement Planning Co of New England Inc.	430,193	$2.50M	1.4%	+11.0%	0.991%
5/7/2024	Mystic Asset Management Inc.	266,297	$1.55M	0.6%	+15.4%	0.613%
5/7/2024	SG Americas Securities LLC	12,680	$74K	0.0%	-39.6%	0.029%
5/1/2024	Janney Montgomery Scott LLC	660,169	$3.83M	0.0%	-3.4%	1.520%
4/25/2024	IFG Advisors LLC	18,700	$0.11M	0.0%	+45.0%	0.043%
2/26/2024	Virtu Financial LLC	26,966	$0.18M	0.0%	N/A	0.074%
2/13/2024	Tower Research Capital LLC TRC	9,673	$63K	0.0%	+134.3%	0.027%
2/13/2024	Armistice Capital LLC	268,000	$1.76M	0.0%	N/A	0.740%
2/12/2024	Focus Financial Network Inc. ADV	21,500	$0.14M	0.0%	N/A	0.059%
2/8/2024	Janney Montgomery Scott LLC	683,431	$4.48M	0.0%	+1.3%	1.887%
2/7/2024	Jump Financial LLC	33,200	$0.22M	0.0%	N/A	0.092%
2/2/2024	Kovack Advisors Inc.	141,401	$0.93M	0.1%	+13.9%	0.390%
1/30/2024	Strs Ohio	19,400	$0.13M	0.0%	+151.9%	0.054%
1/24/2024	International Assets Investment Management LLC	6,550	$43K	0.0%	+555.0%	0.018%
1/12/2024	SG Americas Securities LLC	20,999	$0.14M	0.0%	+41.7%	0.058%
12/6/2023	VisionPoint Advisory Group LLC	6,860	$33K	0.0%	N/A	0.019%
11/15/2023	Laurion Capital Management LP	31,200	$0.15M	0.0%	N/A	0.086%
11/13/2023	Retirement Planning Co of New England Inc.	347,402	$1.67M	0.9%	N/A	0.959%
11/13/2023	Mystic Asset Management Inc.	203,283	$0.98M	0.6%	N/A	0.561%
11/8/2023	Janney Montgomery Scott LLC	674,369	$3.25M	0.0%	N/A	1.988%
11/7/2023	Kingsview Wealth Management LLC	12,120	$58K	0.0%	N/A	0.036%
10/31/2023	IFG Advisors LLC	12,900	$62K	0.0%	N/A	0.038%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	19,072	$92K	0.0%	N/A	0.056%
10/26/2023	Strs Ohio	7,700	$37K	0.0%	N/A	0.023%
10/24/2023	Bank of New York Mellon Corp	202,773	$0.98M	0.0%	N/A	0.598%
10/24/2023	Stratos Wealth Partners LTD.	70,200	$0.34M	0.0%	N/A	0.207%
10/24/2023	Raymond James Financial Services Advisors Inc.	26,228	$0.13M	0.0%	N/A	0.077%
10/23/2023	Commonwealth Equity Services LLC	10,858	$52K	0.0%	N/A	0.032%
10/18/2023	Measured Wealth Private Client Group LLC	10,000	$48K	0.0%	N/A	0.029%
10/16/2023	City State Bank	14,224	$69K	0.0%	N/A	0.042%
10/13/2023	SG Americas Securities LLC	14,824	$71K	0.0%	N/A	0.044%

Data available starting January 2016

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $7.83

$7.50

$8.11

50 Day Range

MA: $6.96

$5.50

$7.88

52 Week Range

Now: $7.83

$3.89

$8.44

Volume

1,002,148 shs

Average Volume

441,503 shs

Market Capitalization

$327.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Who are the company insiders with the largest holdings of Zevra Therapeutics?: Zevra Therapeutics' top insider investors include:
John B Bode (Director)
Richard W Pascoe (CEO)
Thomas Anderson (Director)
Matthew R Plooster (Director)
R Laduane Clifton (CFO)
Timothy J Sangiovanni (SVP)
Joshua Schafer (EVP)
Corey Michael Watton (Director)
Tamara A Seymour (Director)
Learn More about top insider investors at Zevra Therapeutics.
Who are the major institutional investors of Zevra Therapeutics?: Zevra Therapeutics' top institutional shareholders include:
Nantahala Capital Management LLC — 5.78%
Retirement Planning Co of New England Inc. — 1.10%
Mystic Asset Management Inc. — 0.71%
Bank of New York Mellon Corp — 0.53%
Renaissance Technologies LLC — 0.27%
Sanctuary Advisors LLC — 0.20%
Learn More about top institutional investors of Zevra Therapeutics stock.
Which institutional investors are selling Zevra Therapeutics stock?: Within the previous quarter, ZVRA stock was sold by these institutional investors:
Renaissance Technologies LLC
Nantahala Capital Management LLC
Which institutional investors are buying Zevra Therapeutics stock?: Within the previous quarter, ZVRA stock was acquired by institutional investors including:
Sanctuary Advisors LLC
Mystic Asset Management Inc.
Retirement Planning Co of New England Inc.
Bank of New York Mellon Corp
Rhumbline Advisers
The Manufacturers Life Insurance Company
During the previous year, these company insiders have bought Zevra Therapeutics stock:
John B Bode (Director)
Richard W Pascoe (CEO)
Thomas Anderson (Director)
Matthew R Plooster (Director)
R Laduane Clifton (CFO)
Timothy J Sangiovanni (SVP)
Joshua Schafer (EVP)
Corey Michael Watton (Director)
Tamara A Seymour (Director)
Learn More investors buying Zevra Therapeutics stock.